The effect of methylphenidate on pain perception thresholds in children with attention deficit hyperactivity disorder.
Attention deficit hyperactivity disorder
Methylphenidate
Pain perception threshold
Journal
Child and adolescent psychiatry and mental health
ISSN: 1753-2000
Titre abrégé: Child Adolesc Psychiatry Ment Health
Pays: England
ID NLM: 101297974
Informations de publication
Date de publication:
13 Oct 2023
13 Oct 2023
Historique:
received:
24
07
2023
accepted:
02
10
2023
medline:
14
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Pain perception is important in children with attention deficit hyperactivity disorder (ADHD) since they are more likely to experience painful events due to increased accident rates. The aim of this study is to contribute to the literature concerning the relationship between ADHD diagnosis, methylphenidate (MPH) therapy, and pain thresholds, since findings regarding the change in pain perception in children with ADHD are scarce and inconsistent. Children aged 8-13 years constituted both the ADHD group (n = 82) and the healthy controls (n = 41). The ADHD group was divided into two subgroups, ADHD without MPH (not treated pharmacologically) and ADHD with MPH (treated pharmacologically for at least three-months). The Conners' Parent Rating Scale-Revised: Short Form was employed to assess ADHD, a visual analog scale was applied to evaluate chronic pain severity, and a manual pressure algometer was used to assess pain thresholds. Children with ADHD had lower pain thresholds than the healthy controls (P < 0.05). However, lower regional pain thresholds were observed in the ADHD group without MPH compared to both the healthy control and ADHD with MPH groups. Although pain thresholds in the ADHD with MPH group were regionally lower than in the healthy controls, low pain thresholds were found in fewer regions compared to the ADHD without MPH group. Children with ADHD are more sensitive to pain sensation, and MPH may help normalize these individuals' pain experiences by raising pain thresholds. Families and clinicians must be aware of situations that may cause pain in children with ADHD. In addition, these children's low threshold for pain may lead them to experience it more intensely.
Sections du résumé
BACKGROUND
BACKGROUND
Pain perception is important in children with attention deficit hyperactivity disorder (ADHD) since they are more likely to experience painful events due to increased accident rates. The aim of this study is to contribute to the literature concerning the relationship between ADHD diagnosis, methylphenidate (MPH) therapy, and pain thresholds, since findings regarding the change in pain perception in children with ADHD are scarce and inconsistent.
METHODS
METHODS
Children aged 8-13 years constituted both the ADHD group (n = 82) and the healthy controls (n = 41). The ADHD group was divided into two subgroups, ADHD without MPH (not treated pharmacologically) and ADHD with MPH (treated pharmacologically for at least three-months). The Conners' Parent Rating Scale-Revised: Short Form was employed to assess ADHD, a visual analog scale was applied to evaluate chronic pain severity, and a manual pressure algometer was used to assess pain thresholds.
RESULT
RESULTS
Children with ADHD had lower pain thresholds than the healthy controls (P < 0.05). However, lower regional pain thresholds were observed in the ADHD group without MPH compared to both the healthy control and ADHD with MPH groups. Although pain thresholds in the ADHD with MPH group were regionally lower than in the healthy controls, low pain thresholds were found in fewer regions compared to the ADHD without MPH group.
CONCLUSIONS
CONCLUSIONS
Children with ADHD are more sensitive to pain sensation, and MPH may help normalize these individuals' pain experiences by raising pain thresholds. Families and clinicians must be aware of situations that may cause pain in children with ADHD. In addition, these children's low threshold for pain may lead them to experience it more intensely.
Identifiants
pubmed: 37833816
doi: 10.1186/s13034-023-00667-y
pii: 10.1186/s13034-023-00667-y
pmc: PMC10576289
doi:
Types de publication
Journal Article
Langues
eng
Pagination
118Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Pain. 1998 Apr;75(2-3):257-9
pubmed: 9583761
Neuropsychol Rev. 2007 Mar;17(1):39-59
pubmed: 17318414
Exp Brain Res. 1985;58(2):213-26
pubmed: 2987012
J Atten Disord. 2009 Jan;12(4):330-40
pubmed: 19095891
Biol Psychiatry. 2012 Sep 1;72(5):371-7
pubmed: 22386378
Pain. 2013 Jan;154(1):103-109
pubmed: 23158759
Dev Sci. 2005 Mar;8(2):122-31
pubmed: 15720370
Dev Med Child Neurol. 2006 Jun;48(6):483-8
pubmed: 16700941
Biol Psychiatry. 2005 Mar 1;57(5):456-63
pubmed: 15737659
Br J Pharmacol. 2006 Jan;147 Suppl 1:S82-8
pubmed: 16402124
Adv Exp Med Biol. 2009;651:15-35
pubmed: 19731547
Pediatrics. 2019 Oct;144(4):
pubmed: 31570648
Behav Brain Funct. 2013 May 03;9:18
pubmed: 23642255
Ann Pharmacother. 2014 Feb;48(2):209-25
pubmed: 24259638
Child Psychiatry Hum Dev. 2009 Mar;40(1):111-21
pubmed: 18663570
PLoS One. 2015 Jul 30;10(7):e0134417
pubmed: 26225935
Annu Rev Psychol. 2015 Jan 3;66:601-29
pubmed: 25251482
Pain. 2006 Nov;125(1-2):143-57
pubmed: 16777328
Am J Psychiatry. 2003 Nov;160(11):1909-18
pubmed: 14594733
PLoS One. 2015 Aug 26;10(8):e0133143
pubmed: 26308205
J Pers Assess. 2003 Jun;80(3):252-9
pubmed: 12763699
Dev Med Child Neurol. 2003 Aug;45(8):525-35
pubmed: 12882531
Prog Neurobiol. 2002 Apr;66(6):355-474
pubmed: 12034378
Neuro Endocrinol Lett. 2002 Feb;23(1):45-8
pubmed: 11880861
Pain. 2000 Jan;84(1):1-12
pubmed: 10601667
J Adolesc Health. 2004 Oct;35(4):346.e1-9
pubmed: 15830457
Neurosci Biobehav Rev. 2006;30(8):1225-45
pubmed: 17161238
Int J Neuropsychopharmacol. 2014 Dec;17(12):2069-74
pubmed: 24807268
J Neurosci. 2000 Mar 15;20(6):RC65
pubmed: 10704519
J Pain Res. 2019 Oct 18;12:2925-2932
pubmed: 31695481
Hum Mov Sci. 2004 Oct;23(3-4):475-88
pubmed: 15541530
Eur J Paediatr Neurol. 2008 Nov;12(6):461-9
pubmed: 18262449
Expert Rev Neurother. 2008 May;8(5):781-97
pubmed: 18457535
Int J Neuropsychopharmacol. 2014 Mar;17(3):371-81
pubmed: 24103254
Turk Psikiyatri Derg. 2019 Spring;30(1):42-50
pubmed: 31170306
Pain Pract. 2015 Jan;15(1):4-11
pubmed: 24134430
Atten Defic Hyperact Disord. 2014 Sep;6(3):159-73
pubmed: 24997891
Hum Mov Sci. 2006 Feb;25(1):76-89
pubmed: 16442173
J Autism Dev Disord. 2009 Mar;39(3):395-404
pubmed: 18752063
Exp Clin Psychopharmacol. 2010 Apr;18(2):184-201
pubmed: 20384430
J Orofac Pain. 2007 Spring;21(2):133-42
pubmed: 17547125
J Neural Transm (Vienna). 2008;115(2):235-9
pubmed: 17896072
Science. 2020 Mar 20;367(6484):1362-1366
pubmed: 32193325
J Neural Transm (Vienna). 2021 Jul;128(7):939-955
pubmed: 33464422
Arthritis Rheum. 2005 Aug;52(8):2495-505
pubmed: 16052595
J Clin Child Adolesc Psychol. 2002 Jun;31(2):230-41
pubmed: 12056106
Synapse. 2009 May;63(5):390-402
pubmed: 19173266
Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008943
pubmed: 22786518
J Clin Neurophysiol. 1997 Jan;14(1):2-31
pubmed: 9013357
Med Hypotheses. 1989 May;29(1):33-42
pubmed: 2546021
Child Adolesc Psychiatry Ment Health. 2016 Jul 22;10:24
pubmed: 27453723
Headache. 1998 Oct;38(9):710-2
pubmed: 15613186
CNS Spectr. 2005 Dec;10(12 Suppl 20):16-25
pubmed: 16344837
Pain Rep. 2017 Apr 14;2(3):e593
pubmed: 29392209
Neuropsychologia. 2013 Jul;51(8):1649-61
pubmed: 23639477
Eur J Pain. 2004 Oct;8(5):427-33
pubmed: 15324774
J Atten Disord. 2022 Apr;26(6):870-880
pubmed: 34378435
Life Sci. 1999;65(22):2269-87
pubmed: 10597883
Synapse. 2007 Apr;61(4):254-8
pubmed: 17230551
Arch Neurol. 1988 Sep;45(9):973-6
pubmed: 2458094
J Child Psychol Psychiatry. 2002 May;43(4):529-42
pubmed: 12030598